Sugi Predict

Sugi Predict / Compounds / SCHEMBL2097484

SCHEMBL2097484

SCHEMBL2097484

O=C(CBr)c1nc2ccccc2s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.67
▸ NPC1 O15118 4/20 0.67
▸ SMN1; SMN2 Q16637 3/20 0.67
▸ HPGD P15428 3/20 0.67
▸ ALDH1A1 P00352 4/20 0.57
▸ MAPT P10636 3/20 0.56
▸ GAA P10253 1/20 0.56
▸ MCL1 Q07820 1/20 0.56
▸ PKM P14618 1/20 0.54
▸ NFKB1 P19838 1/20 0.54
▸ NFKB2 Q00653 1/20 0.54
▸ RELA Q04206 1/20 0.54
▸ L3MBTL1 Q9Y468 3/20 0.54
▸ ALOX15 P16050 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ CASP1 P29466 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ TP53 P04637 1/20 0.52
▸ HTR1A P08908 3/20 0.52
▸ DRD2 P14416 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16808929 0.86 RAB9A (0.67) RAB9ANPC1SMN1; SMN2HPGDALDH1A1
SCHEMBL10313749 0.83 RAB9A (0.67) RAB9ANPC1SMN1; SMN2HPGDALDH1A1
SCHEMBL6647582 0.83 RAB9A (0.67) RAB9ANPC1SMN1; SMN2HPGDALDH1A1
SCHEMBL569032 0.80 ALDH1A1 (0.67) RAB9ANPC1SMN1; SMN2HPGDALDH1A1
SCHEMBL23617613 0.80 NPC1 (0.63) RAB9ANPC1SMN1; SMN2HPGDALDH1A1
SCHEMBL12548965 0.80 NPC1 (0.63) RAB9ANPC1SMN1; SMN2HPGDALDH1A1
SCHEMBL3594981 0.80 RAB9A (0.63) RAB9ANPC1SMN1; SMN2HPGDALDH1A1
SCHEMBL5973802 0.80 RAB9A (1.00) RAB9ANPC1SMN1; SMN2HPGDALDH1A1
SCHEMBL15332006 0.80 RAB9A (0.63) RAB9ANPC1SMN1; SMN2HPGDALDH1A1
SCHEMBL6319718 0.80 ALDH1A1 (0.66) RAB9ANPC1SMN1; SMN2HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108395428-B Benzothiazole-triazole-isatin type compound and synthesis and application thereof 贵州医科大学 2021-02-02 — — CN claimed
EP-4706757-A2 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2026-03-11 — — EP disclosed
EP-4209490-B1 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) 2026-01-28 — — EP disclosed
US-12473279-B2 Fused imidazole derivative, preparation method therefor, and medical use thereof JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-11-18 — — US disclosed
US-12459937-B2 Fused imidazole derivative, preparation method therefor, and medical use thereof JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-11-04 — — US disclosed
US-20250282773-A1 FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-09-11 — — US disclosed
US-20250243195-A1 FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-07-31 — — US disclosed
CN-119954797-A Condensed imidazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-05-09 — — CN disclosed
CN-119930603-A Condensed imidazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-05-06 — — CN disclosed
CN-119930605-A Condensed imidazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-05-06 — — CN disclosed
US-20080090834-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PFIZER INC 2008-04-17 — — US disclosed
WO-2008029152-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2008-03-13 — — WO disclosed
WO-2008029152-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2008-03-13 — — WO disclosed
WO-2008004117-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-01-10 — — WO disclosed
WO-2008004117-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-01-10 — — WO disclosed
US-20060100235-A1 Pharmaceutical use of substituted 1,2,4-triazoles NOVO NORDISK A/S (DK) 2006-05-11 — — US disclosed
EP-1615637-A1 PHARMACEUTICAL USE OF SUBSTITUTED 1,2,4-TRIAZOLES NOVO NORDISK A/S (DK) 2006-01-18 — — EP disclosed
US-20050049245-A1 Heteroaryl-ethanolamine derivatives as antiviral agents PHARMACIA & UPJOHN COMPANY 2005-03-03 — — US disclosed
WO-2004106345-A2 HETEROARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-12-09 — — WO disclosed
WO-2004089367-A1 PHARMACEUTICAL USE OF SUBSTITUTED 1,2,4-TRIAZOLES NOVO NORDISK A/S (DK) 2004-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090834-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PDE5A, PDE3B, PDE12 RAB9A 870/4885NPC1 1779/4885SMN1; SMN2 1341/4885
US-20050049245-A1 Heteroaryl-ethanolamine derivatives as antiviral agents RPL35, ZC3HAV1, RPL5 RAB9A 1542/4885NPC1 1656/4885SMN1; SMN2 4631/4885
US-12459937-B2 Fused imidazole derivative, preparation method therefor, and medical use thereof GLP1R, GIPR, VIP RAB9A 2268/4885NPC1 1250/4885SMN1; SMN2 4330/4885
US-12473279-B2 Fused imidazole derivative, preparation method therefor, and medical use thereof GLP1R, GIPR, VIP RAB9A 2268/4885NPC1 1250/4885SMN1; SMN2 4330/4885
US-20250282773-A1 FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF GLP1R, GIPR, VIP RAB9A 2268/4885NPC1 1250/4885SMN1; SMN2 4330/4885
US-20250243195-A1 FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF GLP1R, GIPR, VIP RAB9A 2268/4885NPC1 1250/4885SMN1; SMN2 4330/4885
US-20060100235-A1 Pharmaceutical use of substituted 1,2,4-triazoles HSD3B1, HSD11B1, HSD3B2 RAB9A 3808/4885NPC1 376/4885SMN1; SMN2 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.